Aidoc has raised $150 million in a Series E funding round, bringing total investment in the clinical AI company to more than $500 million.
The new capital will support further development of Aidoc's CARE (Clinical AI Reasoning Engine) foundation model, expansion into additional clinical indications, and new capabilities such as automated imaging draft report creation, Aidoc said. It will also drive broader global deployment of its aiOS enterprise AI platform, the firm noted.
The round was led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Investment Advisors, and NVentures, NVIDIA's venture capital arm, the company said.
Aidoc noted that its technology analyzes more than 60 million patient cases annually and is deployed across nearly 2,000 hospitals worldwide.
